Search results for: antibody
#34706311 2021/10/16 To Up
Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion. We sought to determine if the addition of denosumab (a monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand - RANKL) to intensive urate-lowering therapy (ULT) improves gouty bone erosion.
Angelo L Gaffo, Kenneth Saag, Anthony J Doyle, Joshua Melnick, Anne Horne, Jeffrey Foster, Amy Mudano, Stephanie Biggers-Clark, David Redden, Nicola Dalbeth
1741 related Products with: Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.100 100 μg100 100 μg1 mg
Error loading info... Pleas try again later.
#34706271 2021/10/16 To Up
Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here, we report the cryo-EM structure of a potent NTD-directed neutralizing antibody 5-7, which recognizes a site distinct from other potently neutralizing antibodies, inserting a binding loop into an exposed hydrophobic pocket between the two sheets of the NTD Î² sandwich. Interestingly, this pocket was previously identified as the binding site for hydrophobic molecules, including heme metabolites, but we observe that their presence does not substantially impede 5-7 recognition. Mirroring its distinctive binding, antibody 5-7 retains neutralization potency with many variants of concern (VOCs). Overall, we reveal that a hydrophobic pocket in NTD proposed for immune evasion can be used by the immune system for recognition.
Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S Katsamba, Fabiana Bahna, Eswar R Reddem, Peter D Kwong, David D Ho, Zizhang Sheng, Lawrence Shapiro
1251 related Products with: Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.100 ug100ug100ug Lyophilized100μg200ul250ul100 ug100ug Lyophilized250ul100ug Lyophilized100 ug200ul
#34706189 2021/10/27 To Up
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Diego R Falci, Elias Sarkis, Joel Solis, Hanzhe Zheng, Nicola Scott, Andrea L Cathcart, Christy M Hebner, Jennifer Sager, Erik Mogalian, Craig Tipple, Amanda Peppercorn, Elizabeth Alexander, Phillip S Pang, Almena Free, Cynthia Brinson, Melissa Aldinger, Adrienne E Shapiro,
2746 related Products with: Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.100ug Lyophilized200ul1 mg200ul200ul100ug Lyophilized200ug200ul200ul200ul100 200ul
#34706178 // To Up
Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.
Eric J Rubin, Lindsey R Baden, Stephen Morrissey
1787 related Products with: Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.0.2 mg25 µg25 µg0.25 mg100 TESTS0.2 mg1 ml 1 G 100ul 100ul100μg 100ul
No related Items
#34706172 // To Up
Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.
Christopher E Brightling, Parameswaran Nair, David J Cousins, Renaud Louis, Dave Singh5 100 μg1 mg100 μg100 μg100 μg3 mg100 μg100 μg
#34706171 // To Up
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33. The efficacy and safety of itepekimab as monotherapy, as well as in combination with dupilumab, in patients with asthma are unclear.
Michael E Wechsler, Marcella K Ruddy, Ian D Pavord, Elliot Israel, Klaus F Rabe, Linda B Ford, Jorge F Maspero, Raolat M Abdulai, Chih-Chi Hu, Renata Martincova, Andreas Jessel, Michael C Nivens, Nikhil Amin, David M Weinreich, George D Yancopoulos, Helene Goulaouic
1759 related Products with: Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.1 Set100ul1 mg1 Set100 ug2 105
#34706153 2021/10/27 To Up
First evidence of human-to-dog transmission of SARS-CoV-2 B.1.160 variant in France.Since the start of the COVID-19 pandemic, several episodes of human-to-animal SARS-CoV-2 transmission have been described in different countries. The role of pets, especially domestic dogs, in the COVID-19 epidemiology is highly questionable and needs further investigation. In this study, we report a case of COVID-19 in a French dog living in close contact with its owners who were COVID-19 patients. The dog presented rhinitis and was sampled one week after its owners (a man and a woman) were tested positive for COVID-19. The nasal swabs for the dog tested remained positive for SARS-CoV-2 by RT-qPCR one month following the first diagnosis. Specific anti- SARS-CoV-2 antibodies were detectable 12 days after the first diagnosis and persisted for at least five months as tested using ELISA and automated western blotting. The whole-genome sequences from the dog and its owners were 99%-100% identical (with the man and the woman's sequences, respectively) and matched the B.1.160 Variant of concern (Marseille-4 variant), the most widespread in France at the time the dog was infected. This study documents the first detection of B.1.160 in pets (a dog) in France, and the first canine genome recovery of the B.1.160 variant of global concern. Moreover, given the enhanced infectivity and transmissibility of the Marseille-4 variant for humans, this case also highlights the risk that pets may potentially play a significant role in SARS-CoV-2 outbreaks and may transmit the infection to humans. We have evidence of human-to-dog transmission of the Marseille-4 variant, since the owners were first to be infected. Finally, owners and veterinarians must be vigilent for canine COVID-19 when dogs are presented with respiratory clinical signs. This article is protected by copyright. All rights reserved.
HacÃ¨ne Medkour, SÃ©bastien Catheland, Corine Boucraut-Baralon, Younes Laidoudi, Youssouf Sereme, Jean-Luc Pingret, Matthieu Million, Linda Houhamdi, Anthony Levasseur, Julien Cabassu, Bernard Davoust
2808 related Products with: First evidence of human-to-dog transmission of SARS-CoV-2 B.1.160 variant in France.100ug Lyophilized20ug100ug Lyophilized100ug Lyophilized25mg100ug Lyophilized20ug1016 Arrays/Slide100 μg2
Error loading info... Pleas try again later.
#34706134 2021/10/27 To Up
Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.COVID-19 pandemic caused by SARS-CoV-2 has become a public health crisis worldwide. In this study we aimed at demonstrating the neutralizing potential of the IgY produced after immunizing chicken with a recombinant SARS-CoV-2 spike protein S1 subunit.
Lirong Bao, Cheng Zhang, Jinglu Lyu, Ping Yi, Xin Shen, Boyu Tang, Hang Zhao, Biao Ren, Yu Kuang, Linlin Zhou, Yan Li
2268 related Products with: Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.100 100200ul100 100 G500200ug1 kit25ml200ul1000
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia